Affimed (NASDAQ:AFMD) Short Interest Up 14.5% in March

Affimed (NASDAQ:AFMD) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 196,400 shares, a growth of 14.5% from the March 15th total of 171,600 shares. Based on an average daily volume of 98,300 shares, the days-to-cover ratio is currently 2.0 days. Currently, 1.5% of the shares of the stock are sold short.

Affimed Stock Performance

Shares of Affimed stock traded down $0.17 during trading on Tuesday, reaching $5.32. The company’s stock had a trading volume of 12,363 shares, compared to its average volume of 98,629. The firm has a market cap of $81.02 million, a PE ratio of -0.63 and a beta of 2.05. The business’s 50-day moving average price is $5.56 and its 200-day moving average price is $5.00. Affimed has a 52 week low of $2.23 and a 52 week high of $11.10. The company has a quick ratio of 3.23, a current ratio of 3.25 and a debt-to-equity ratio of 0.11.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its stake in Affimed by 21.0% in the second quarter. JPMorgan Chase & Co. now owns 83,372 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 14,477 shares in the last quarter. Bank of America Corp DE raised its stake in Affimed by 461.2% in the first quarter. Bank of America Corp DE now owns 230,273 shares of the biopharmaceutical company’s stock valued at $1,006,000 after purchasing an additional 189,243 shares in the last quarter. Virtu Financial LLC acquired a new position in Affimed in the first quarter valued at about $102,000. Wellington Management Group LLP raised its stake in Affimed by 6.4% in the first quarter. Wellington Management Group LLP now owns 520,127 shares of the biopharmaceutical company’s stock valued at $2,273,000 after purchasing an additional 31,331 shares in the last quarter. Finally, State Street Corp raised its stake in Affimed by 3.3% in the first quarter. State Street Corp now owns 2,112,912 shares of the biopharmaceutical company’s stock valued at $9,233,000 after purchasing an additional 67,761 shares in the last quarter. Institutional investors and hedge funds own 30.82% of the company’s stock.

Wall Street Analysts Forecast Growth

AFMD has been the topic of several recent research reports. Wells Fargo & Company reduced their target price on shares of Affimed from $30.00 to $25.00 and set an “overweight” rating on the stock in a research note on Monday, April 1st. StockNews.com began coverage on shares of Affimed in a report on Tuesday, January 2nd. They set a “sell” rating on the stock. HC Wainwright lifted their price objective on shares of Affimed to $10.00 and gave the company a “buy” rating in a report on Monday, April 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a report on Monday, April 1st. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $45.00.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.